SELLAS reports a 41% lower risk of death with galinpepimut-S in Phase 3 REGAL, improving median overall survival to 24 months in AML.
Written By: Aasritha Thippavajjala, PharmD
Reviewed By: Pharmacally Editorial Team
SELLAS Life Sciences announced positive topline results from the pivotal Phase 3 REGAL trial of galinpepimut-S (GPS), an investigational WT1-targeting immunotherapeutic cancer vaccine, in patients with acute myeloid leukemia (AML). The trial met its primary endpoint of overall survival (OS), demonstrating a statistically significant reduction in the hazard of death compared with best available treatment (BAT).
Announced on November 17, 2026, the results showed a hazard ratio (HR) of 0.59, corresponding to a 41% lower hazard of death in patients receiving GPS. Median OS was 24.0 months with GPS compared with 14.7 months with BAT, with a two-sided p-value of 0.035.
REGAL Phase 3 Trial: Study Design and Patient Population
REGAL (NCT04229979) was a global, randomized, open-label, registrational Phase 3 trial evaluating GPS as maintenance monotherapy in patients with AML who achieved a second or later complete remission (CR2 or later), or complete remission with insufficient platelet recovery (CRp2 or later), following second- or later-line salvage therapy. Participants were ineligible for, or unable to undergo, allogeneic hematopoietic stem cell transplantation.
A total of 126 patients were randomized 1:1 to receive GPS or investigator-selected BAT. Treatment options in the control arm included observation, hypomethylating agents, venetoclax, low-dose cytarabine, or combinations of these approaches.
The primary endpoint was OS measured from study entry. Secondary endpoints included safety and tolerability, leukemia-free survival, landmark OS, relapse-free survival in patients with prior transplantation, WT1-specific T-cell responses, measurable residual disease (MRD), and other molecular and clinical assessments.
The primary analysis was conducted after the prespecified 80th death event, in accordance with the trial’s statistical analysis plan.
Galinpepimut-S Demonstrates Overall Survival Benefit
The primary analysis showed a statistically significant OS benefit with GPS compared with BAT.
Key topline findings included:
- Median overall survival: 24.0 months with GPS versus 14.7 months with BAT.
- Reduction in hazard of death: 41%.
- Hazard ratio: 0.59.
- Statistical significance: Two-sided p=0.035.
The treatment groups were reported to be well balanced for prognostic stratification factors. A limited number of patients proceeded to hematopoietic stem cell transplantation after study entry, with these patients equally distributed between the two groups.
The findings represent a positive primary endpoint result in a population with limited post-remission treatment options when transplantation is not feasible. However, the reported median survival difference should be interpreted alongside the hazard ratio and p-value rather than as evidence of a uniform survival extension for individual patients.
SELLAS said comprehensive statistical analyses of secondary endpoints and other prespecified assessments are ongoing. Detailed findings are expected to be presented at an upcoming major medical conference and submitted for publication in a peer-reviewed journal.
Safety and Tolerability
GPS was generally well tolerated, according to SELLAS, with a safety profile consistent with previous clinical experience and no new safety signals identified. Treatment-related adverse events were predominantly Grade 1 or 2, with local injection-site reactions reported most commonly.
Detailed adverse event frequencies, serious adverse events and treatment discontinuation data have not yet been disclosed in the topline announcement. The complete safety dataset will be important for assessing the treatment’s overall benefit-risk profile.
Galinpepimut-S: Targeting WT1 Through Immunotherapy
GPS is an investigational, off-the-shelf immunotherapeutic cancer vaccine designed to stimulate CD4-positive and CD8-positive T-cell responses against cells expressing Wilms’ tumor 1 (WT1), a protein expressed in AML and several other hematological malignancies and solid tumors.
Licensed from Memorial Sloan Kettering Cancer Center, GPS was discovered through research in David A. Scheinberg’s laboratory. It comprises four WT1-derived peptides designed to generate an immune response across multiple human leukocyte antigen (HLA) types.
The vaccine is being developed as maintenance therapy intended to target residual WT1-expressing leukemia cells following remission. REGAL evaluated GPS as monotherapy, and its findings do not establish clinical outcomes with combination regimens or in other cancer indications.
Regulatory Development
SELLAS plans to discuss the results and a potential accelerated filing strategy with the US Food and Drug Administration (FDA). The company is also advancing preparations for a Biologics License Application (BLA), targeting submission in the first half of 2027.
The proposed regulatory pathway remains subject to FDA discussions and review of the complete clinical dataset. The company has cautioned that further analyses could differ from the topline findings and may not necessarily support regulatory submission or approval.
GPS remains investigational, and the positive Phase 3 topline results do not constitute regulatory approval.
Clinical Interpretation
The REGAL findings provide randomized Phase 3 evidence of a statistically significant OS benefit with a WT1-targeting maintenance immunotherapy in a high-risk AML population unable to undergo allogeneic transplantation. The median OS of 24.0 months and HR of 0.59 support further evaluation of GPS as a potential maintenance treatment in this setting.
Nevertheless, the announcement provides topline findings rather than a complete clinical dataset. The absence of reported confidence intervals, detailed secondary endpoint results and comprehensive safety analyses limits independent assessment of the robustness and broader clinical implications of the survival benefit. These data, together with the forthcoming FDA discussions, will be important in determining the potential regulatory and clinical role of GPS.
References
SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia, SELLAS Life Sciences, November 17, 2026
Galinpepimut-S Versus Investigator’s Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (REGAL), ClinicalTrials.gov ID NCT04229979
About the Writer
Aasritha Thippavajjala (Linkedin) is a pharm D student and aspiring medical writer with medical writing, clinical training experience and a strong interest in clinical research and patient safety She has hands-on exposure to clinical pharmacy activities including medication profile assessment, clinical case review, identification of potential drug-related problems, ADR awareness, patient counselling, and clinical documentation. She has also gained experience in medical literature review, evidence synthesis, and scientific communication through her published review article on digital twin-based patient simulation and her poster presentation at the 74th Indian Pharmaceutical Congress. Certified in ICH Good Clinical Practice (E6(R3)) and Scientific Writing in Health Research, she is passionate about applying her clinical knowledge and research skills to medical writing ,clinical research and contributing to accurate, evidence-based healthcare.
